BioLineRx Ltd
Modi'in-Maccabim-Re'ut, Center District, Israel · Biopharma, Biotechnology, Healthcare
BioLineRx is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, p
Key facts
- Headquarters
- Modi'in-Maccabim-Re'ut, Center District, Israel
- Employees
- 28
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (BLRX)
- Website
- biolinerx.com
- Company page
Recent activity at BioLineRx Ltd
BioLineRx Ltd funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Seed | $3.8M |
| Apr 2024 | Pre-Seed | $20 |
| Jun 2020 | Venture | $9.0M |
| Jun 2020 | Pre-Seed | $4.4M |
Leadership
- Aharon Schwartz, Director
- Michael Anghel, Director
- Nurit Benjamini, Director
- Barbara Bormann, Director
- Raphael Hofstein, Director
- Avraham Molcho, Director
- Sandra Panem, Director
- Aharon Schwartz, Director
- Michael Anghel, Director
- Nurit Benjamini, Director
- Barbara Bormann, Director
- Raphael Hofstein, Director
Verified email and direct lines for BioLineRx Ltd’s decision-makers are on Fundz. See plans
BioLineRx Ltd in the news
- BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - Lelezard (Oct 01, 2026)
- BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire (Aug 31, 2026)
- BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 - Yahoo Finance (Aug 25, 2026)
- BioLineRx Reports 2025 Financial Results and Provides Corporate Update - PR Newswire (Mar 23, 2026)
- BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model – Company Announcement - Financial Times (Jul 08, 2026)
- BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination - MultiVu (Sep 11, 2023)
- BioLineRx will release second-quarter results before U.S. markets open Aug. 31 - Stock Titan (Aug 25, 2026)
- A drug candidate cut tumor growth and extended survival in mice. Human testing is enrolling. - Stock Titan (Sep 10, 2026)
Companies similar to BioLineRx Ltd
- Tempest Therapeutics · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Cantargia AB · Biopharma, Biotechnology, Health Care, research, Therapeutics
- Aarvik Therapeutics · Biotechnology, Healthcare, Health Care, research, Therapeutics
- Takis S.r.l · Biopharma, Biotechnology, Health Care, research, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
About BioLineRx Ltd: questions and answers
What does BioLineRx Ltd do?
BioLineRx is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, p
Where is BioLineRx Ltd headquartered?
BioLineRx Ltd is headquartered in Modi'in-Maccabim-Re'ut, Center District, Israel.
How many employees does BioLineRx Ltd have?
BioLineRx Ltd has about 28 employees.
Has BioLineRx Ltd raised funding?
Yes. Fundz has recorded 4 funding events for BioLineRx Ltd. The most recent, Seed of $3.8M, was in Sep 2026.
What is the latest news on BioLineRx Ltd?
On Sep 09, 2026, BioLineRx Ltd
Is BioLineRx Ltd a public company?
Yes. BioLineRx Ltd is publicly traded under the ticker BLRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy